PolyPid Ltd.

NasdaqCM PYPD

PolyPid Ltd. Gross Profit for the year ending December 31, 2023: USD -1.82 M

PolyPid Ltd. Gross Profit is USD -1.82 M for the year ending December 31, 2023, a -5.87% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

PolyPid Ltd. Gross Profit for the year ending December 31, 2022 was USD -1.72 M, a -53.94% change year over year.
PolyPid Ltd. Gross Profit for the year ending December 31, 2021 was USD -1.12 M, a -10.47% change year over year.
PolyPid Ltd. Gross Profit for the year ending December 31, 2020 was USD -1.01 M, a -6.86% change year over year.
PolyPid Ltd. Gross Profit for the year ending December 31, 2019 was USD -947.00 K, a -130.41% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqCM: PYPD

PolyPid Ltd.

CEO	Ms. Dikla Czaczkes Akselbrad
IPO Date	June 26, 2020
Location	Israel
Headquarters	18 Hasivim Street
Employees	59
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Key trends

Past 5 years